Mesodermal Killer Cells for Direct Tumor Lysis and NK Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current mesenchymal stem cell (MSC) therapies for treating cancer are limited by the use of mixed subtypes lacking immuno-modulatory properties, requiring high cell doses that can cause side effects and are difficult to obtain in sufficient quantities, and they typically differentiate into replacement tissues rather than directly targeting cancer cells.
Innovation Solution
Development of mesodermal killer (MK) cells, which express specific markers (CD112, CD137L, CD178, CD253, CD277) and lack CD34 and CD45, capable of directly killing cancer cells and priming/activating natural killer (NK) cells, produced from mononuclear cells under controlled conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If MSCs are used for cancer therapy, then therapeutic effects are achieved through paracrine signaling and cell migration to damaged tissue, but high cell doses are required which cause off-target side effects and volume-related side effects
Solution Approach 1:
The patent applies local quality by directing MSCs to specifically target tumor tissues through chemotactic responses to CXCL12, rather than distributing them systemically. The modified MSCs express CXCR4 receptors that respond to CXCL12 gradients, concentrating the therapeutic effect locally at the tumor site and reducing off-target exposure to healthy tissues.
Solution Approach 2:
The patent uses CXCL12 as an intermediary molecule to guide MSCs to tumor sites. The chemokine creates a chemical gradient that mediates the定向 migration of MSCs, acting as a signaling intermediary between the tumor microenvironment and the therapeutic cells, thereby achieving precise targeting without requiring high systemic doses.
2Quantity of substance
If high cell doses of MSCs are administered, then therapeutic coverage is sufficient, but volume-related side effects and off-target effects increase
Solution Approach 1:
The patent extracts and utilizes the chemotactic guidance mechanism by introducing CXCR4 expression in MSCs and utilizing endogenous or exogenously administered CXCL12 gradients. This extraction of the directional migration capability allows low doses of cells to be effectively concentrated at tumor sites, eliminating the need for high systemic doses that cause volume-related side effects.
Solution Approach 2:
The patent changes the parameter of cell dose from high to low by implementing targeted delivery. The modified MSCs maintain therapeutic efficacy at lower concentrations because they are actively guided to tumor sites through CXCR4-CXCL12 interactions, transforming the dosing strategy from quantity-dependent to precision-dependent therapy.
3Ease of manufacture
If MSCs are obtained from bone marrow, then source is available, but large numbers of cells are difficult to obtain
Solution Approach 1:
The patent applies universality by demonstrating that MSCs can be obtained from multiple tissue sources including bone marrow, adipose tissue, and umbilical cord. This multi-source capability ensures adequate cell yield for therapy while maintaining the desired immunomodulatory and regenerative properties of MSCs regardless of origin.
Solution Approach 2:
The patent employs preliminary action by expanding MSCs in culture prior to administration and by potentially using exogenous CXCL12 pre-treatment to enhance homing efficiency. This preliminary expansion and priming allows sufficient cell numbers to be obtained from limited harvests while ensuring optimal therapeutic performance upon administration.
4Productivity
If mixed MSC subtypes are used, then cell availability is improved, but immuno-modulatory properties are lacking
Solution Approach 1:
The patent applies local quality by selecting and utilizing specific MSC subtypes with proven immuno-modulatory capabilities rather than using heterogeneous mixed populations. The selected subtypes are characterized for their specific immunomodulatory phenotypes and are deployed in a controlled manner to ensure consistent therapeutic effects at the target site.
Solution Approach 2:
The patent changes the parameter of cell subtype composition from mixed to selected by imposing specific phenotypic criteria on the MSC population. This selection process enriches for subtypes with enhanced immuno-modulatory properties while maintaining adequate cell availability for therapeutic administration.
Data Source
AI summary
The invention relates to mesodermal killer (MK) cells and their use in therapy, especially for the treatment of cancer.